IMAGING BIOMARKERS ALLIANCE
EIBALL
European Imaging Biomarkers Alliance.
The activities of the former ESR Subcommittee on Imaging Biomarkers, ESR Working Group on Personalised Medicine and ESR-EORTC Working Group were merged into EIBALL to facilitate imaging biomarker development, standardization and promote their use in clinical trials and in clinical practice by collaboration with specialist societies, international standards agencies and trials organisations to develop a network of excellence.
EIBALL has set itself the following Objectives:
- Coordinate all ESR activities concerning imaging biomarkers
- Prepare an inventory of all activities and projects in the field of imaging biomarkers where the ESR is involved
- Serve as a tool box that provides information about current projects, centres involved in clinical trials and educational activities
- Define possible imaging biomarkers in different human body regions; oncologic as well as non-oncologic
- Establish a functional biomarker profile that is current and relevant through the development of an online inventory of biomarkers
- Enable and encourage the clinical use of biomarkers by setting standards for data acquisition and image processing
- Closely collaborate with EIBIR to maintain an updated list of European centres of excellence (core institutions) for the implementation and clinical validation of imaging biomarkers
- Closely collaborate with the EORTC (European Organisation for Research and Treatment of Cancer) and its Imaging Group with regard to the inclusion of radiologists in multicentre trials and the development of a biomarker inventory
- Closely collaborate with QIBA (technical validation synergies) to avoid duplication of development and EORTC (biological validation) to coordinate strategies, find complementarity, and benefit from synergiess
BIOMARKER INVENTORY
EIBALL has designed a biomarker inventory to provide a reference for researchers and trialists, listing what biomarkers exist and what evidence for their use exists, so that these biomarkers can be incorporated into clinical trials so as to start building an evidence base.
EIBALL at ECR 2024
The EIBALL Subcommittee held two sessions at ECR 2024. It can be accessed online via the ESR’s Premium Education Package:
EIBALL collaborates with the Quantitative Imaging Biomarkers Alliance (QIBA). QIBA is an important part of the Radiological Society of North America’s (RSNA) commitment to transforming radiology from a qualitative to a more quantitative science and to the improved patient care resulting from accelerated development and dissemination of new pharmacologic, biologic and interventional diagnosis and treatment approaches.
Consensus Documents
Consensus Recommendation on the display of colour maps for MR relaxometry have been released by the quantitative imaging study group of the International Society of Magnetic Resonance in Medicine.
The logarithm-processed Lipari colour map for displaying T1 and R1 values and the logarithm-processed Navia colour-map for displaying T2, R2 , T2* and R2* are recommended for use in scientific reports and ideally in clinical practice (https://doi.org/10.1002/mrm.30290). Links for the generation of these maps in Matlab or Julia may be found here: https://doi.org/10.5281/zenodo.8268884
(for other packages, please implement the algorithm as described in the appendix of the paper).
The Institute of Cancer Research: Royal Cancer Hospital, a charitable Company Limited by Guarantee, Registered in England under Company No. 534147 with its Registered Office at 123 Old Brompton Road, London SW7 3RP.
This e-mail message is confidential and for use by the addressee only. If the message is received by anyone other than the addressee, please return the message to the sender by replying to it and then delete the message from your computer and network.
The Institute of Cancer Research: Royal Cancer Hospital, a charitable Company Limited by Guarantee, Registered in England under Company No. 534147 with its Registered Office at 123 Old Brompton Road, London SW7 3RP.
This e-mail message is confidential and for use by the addressee only. If the message is received by anyone other than the addressee, please return the message to the sender by replying to it and then delete the message from your computer and network.”